Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

1 Beaten-Down Stock That's Still Not Worth Buying

TheMotleyFool

0 0

1 Beaten-Down Stock That's Still Not Worth Buying: https://g.foolcdn.com/editorial/images/767745/doctor-vaccinating-a-patient.jpg

Investing basics tell us to "buy low" and invest in a stock when there looks to be significant upside potential. That can often be after a company gets put through the wringer and the stock declines substantially. However, sometimes it's not worth investing in a company no matter how much its shares fall.

Case in point: Novavax (NASDAQ: NVAX) is a biotech stock down by 97% over the past three years, yet the stock still doesn't look attractive. Read on to find out why.